Blumenfeld, Shiri <br/><br/>
Fingolimod therapy modulates circulating B cell composition, increases B regulatory subsets and production of IL-10 and TGFβ in patients with Multiple Sclerosis.  [electronic resource] 

 -  Journal of autoimmunity  06 2016 
 - 40-51 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1095-9157 
<br/><br/><label>Standard No.: </label>10.1016/j.jaut.2016.03.012  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Antigen Presentation--immunology<br/>B-Lymphocyte Subsets--cytology<br/>Cell Differentiation--drug effects<br/>Cell Survival--drug effects<br/>Cytokines--metabolism<br/>Female<br/>Fingolimod Hydrochloride--pharmacology<br/>Gene Expression<br/>Humans<br/>Immunologic Memory<br/>Immunophenotyping<br/>Immunosuppressive Agents--pharmacology<br/>Inflammation Mediators--metabolism<br/>Interleukin-10--biosynthesis<br/>Leukocyte Count<br/>Lymphocyte Activation<br/>Lymphocyte Count<br/>Male<br/>Middle Aged<br/>Multiple Sclerosis--diagnosis<br/>Plasma Cells--immunology<br/>Receptors, Lysosphingolipid--genetics<br/>Sphingosine-1-Phosphate Receptors<br/>Transforming Growth Factor beta--biosynthesis<br/>Young Adult